Preference for Emicizumab over Prior Factor Treatments: Results from the HAVEN 3 and HAVEN 4 Studies

ConclusionsAlmost all patients in HAVEN 3 and all patients in HAVEN 4 preferred emicizumab to their prior treatment. These results likely reflect the high efficacy and lower treatment burden previously reported. Such strong preference will be important for individuals currently receiving either episodic or prophylactic treatment when considering emicizumab prophylaxis in the future and may be associated with improved adherence, a substantial clinical obstacle with FVIII or BPAs.DisclosuresJimenez-Yuste: Roche: Consultancy, Research Funding; Shire: Consultancy, Research Funding; Bayer: Consultancy, Research Funding; Sobi: Consultancy, Research Funding; Octapharma: Consultancy, Research Funding; CSL Behring: Consultancy; Grifols: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; NovoNordisk: Consultancy, Research Funding. Shima: F. Hoffmann-La Roche Ltd: Membership on an entity's Board of Directors or advisory committees; Chugai Pharmaceutical Co., Ltd: Consultancy, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties: Anti-FIXa/X bispecific antibodies , Research Funding, Speakers Bureau. Paz-Priel: Genentech Inc: Employment. Parnes: Genentech Inc: Research Funding; Biogen Idec: Research Funding; F. Hoffmann-La Roche Ltd: Research Funding; Shire: Research Funding; Bayer: Membership on an entity's Board of Directors or advisory committees; Shire: Membership on an entity's Board of Directors or advisory committees. Lehle...

Source: Blood - November 21, 2018 Category: Hematology Authors: Jimenez-Yuste, V., Shima, M., Paz-Priel, I., Parnes, A., Lehle, M., Giermasz, A., Campinha-Bacote, A., Niggli, M., Windyga, J., Chebon, S., Trask, P., Mahlangu, J., Pipe, S., Oldenburg, J. Tags: 322. Disorders of Coagulation or Fibrinolysis: Poster I Source Type: research